chemieunternehmen.com

Evotec AG and Exscientia Ltd (Dundee, UK) today announced a collaboration with the objective to discover and develop first-in-class bispecific small molecule immuno-oncology therapies. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-and-exscientia-announce-partnership-to-discover-bispecific-small-molecule-immuno-oncology-therapeutics-5356

Evotec AG today announced a multi-year compound management agreement with Pierre Fabre Laboratories, the 2nd largest private French pharmaceutical group. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-and-pierre-fabre-sign-multi-year-compound-management-agreement-5354

Evotec AG today announced the formation of a spin-off company in the field of nanoparticle-based therapeutics to treat immunological disorders. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-spins-off-auto-immune-disease-company-as-topas-therapeutics-gmbh-5350

Evotec AG today announced its financial results for the fiscal year ended 31 December 2015. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-fy-2015-excellent-execution-meets-first-in-class-innovation-5352

Hamburg, Germany – 15 March 2016: Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX, ISIN: DE0005664809) will report its financial results for 2015 on Tuesday, 22 March 2016. The Company is going to hold a conference call to … Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-ag-fiscal-year-2015-results-presentation-on-22-march-2016-5348

Evotec AG today announced the achievement of a key pre-clinical milestone in the ongoing alliance with its research partner Padlock Therapeutics, Inc. („Padlock“). Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-achieves-milestone-in-collaboration-with-padlock-therapeutics-5346

Hamburg, Germany – 03 March 2016: Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX, ISIN: DE0005664809) announced today that its CEO, Dr Werner Lanthaler, will present at the BioCapital Europe 2016 in Amsterdam, The Netherlands, … Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-to-present-at-ir-conference-5344

Evotecs nächstes Webinar “The preclinical clinical interface: A key to translational success in Oncology” findet am Donnerstag, den 10. März 2016 um 10.00 Uhr EST / 15.00 Uhr GMT statt und wird unter anderem … Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/the-preclinical-clinical-interface-a-key-to-translational-success-in-oncology-5340

Evotec AG today announced that it has been awarded a research grant from The Michael J. Fox Foundation („MJFF“) to further develop Evotec’s TargetaSN (Targetalpha-synuclein) programme for the treatment of Parkinson’s disease. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-awarded-grant-from-the-michael-j-fox-foundation-for-parkinsons-research-5339